Cumberland Pharmaceuticals, Pernix Therapeutics Partner to Promote H. Pylori Treatment

Cumberland Pharmaceuticals and Pernix Therapeutics have come to an agreement to distribute Omeclamox-Pak in the United States.

Omeclamox-Pak is an FDA-approved prescription drug that combines several drug therapies for treatment of Helicobacter pylori infection and duodenal ulcer disease.

Cumberland will promote the drug to its gastroenterologists, and Pernix will promote the produce to its primary care physicians.

More Articles on Gastroenterology:
gMed Announcces gInsights Business & Clinical Intelligence Platform
Stay Competitive: 5 Enhancements for GI/Endoscopy Groups
gGastro EHR System Receives Full EHR Certification

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast